Literature DB >> 35034080

Characteristics, treatment, and control of hypertension in public primary healthcare centers in Nigeria: baseline results from the Hypertension Treatment in Nigeria Program.

Dike B Ojji1,2, Abigail S Baldridge3, Ikechukwu A Orji1, Gabriel L Shedul1, Tunde M Ojo1, Jiancheng Ye3, Aashima Chopra3, Boni M Ale1, Grace Shedul1, Eugenia N Ugwuneji1, Nonye B Egenti1,2, Kasarachi Aluka-Omitiran1, Rosemary C B Okoli4, Helen Eze1, Ada Nwankwo1, Bolanle Banigbe5, Priya Tripathi3, Namratha R Kandula3, Lisa R Hirschhorn3, Mark D Huffman3,6,7.   

Abstract

BACKGROUND: There are limited data on large-scale, multilevel implementation research studies to improve hypertension diagnosis, treatment, and control rates at the primary healthcare (PHC) level in Africa. We describe the characteristics, treatment, and control rates of patients with hypertension in public PHC centers in the Hypertension Treatment in Nigeria Program.
METHODS: Data were collected from adults at least 18 years at 60 public PHC centers between January 2020 and November 2020. Hypertension treatment rates were calculated at registration and upon completion of the initial visit. Hypertension control rates were calculated based on SBP and DBPs less than 140/90 mmHg. Regression models were created to evaluate factors associated with hypertension treatment and control status.
RESULTS: Four thousand, nine hundred and twenty-seven individuals [66.7% women, mean (SD) age = 48.2 (12.9) years] were included. Mean (SD) SBP was higher in men compared with women [152.9 (20.0) mmHg versus 150.8 (21) mmHg, P = 0.001]. Most (58.3%) patients were on treatment at the time of registration, and by the end of the baseline visit, 89.2% of patients were on treatment. The baseline hypertension control rate was 13.1%, and control was more common among patients who were older [adjusted OR (95% CI) 1.01 [1.01 -1.02)], women [adjusted OR (95% CI) 1.30 (1.05- 1.62)], who used fixed dose combination therapy [adjusted OR (95% CI) 1.83 (1.49 -2.26)], and had higher education levels.
CONCLUSION: This baseline report of the largest facility-based hypertension study in Africa demonstrates high hypertension treatment rates but low control rates.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35034080      PMCID: PMC9081131          DOI: 10.1097/HJH.0000000000003089

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.776


  17 in total

1.  Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact.

Authors:  Geoffrey M Curran; Mark Bauer; Brian Mittman; Jeffrey M Pyne; Cheryl Stetler
Journal:  Med Care       Date:  2012-03       Impact factor: 2.983

2.  The clinical consequences and challenges of hypertension in urban-dwelling black Africans: insights from the Heart of Soweto Study.

Authors:  Simon Stewart; Elena Libhaber; Melinda Carrington; Albertino Damasceno; Haroon Abbasi; Craig Hansen; David Wilkinson; Karen Sliwa
Journal:  Int J Cardiol       Date:  2009-06-26       Impact factor: 4.164

3.  Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Abdul Salam; Raju Kanukula; Emily Atkins; Xia Wang; Shariful Islam; Sandeep P Kishore; Marc G Jaffe; Anushka Patel; Anthony Rodgers
Journal:  J Hypertens       Date:  2019-09       Impact factor: 4.844

4.  Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A Systematic Review and Meta-analysis.

Authors:  Katherine T Mills; Katherine M Obst; Wei Shen; Sandra Molina; Hui-Jie Zhang; Hua He; Lisa A Cooper; Jiang He
Journal:  Ann Intern Med       Date:  2017-12-26       Impact factor: 25.391

Review 5.  Interventions used to improve control of blood pressure in patients with hypertension.

Authors:  Liam G Glynn; Andrew W Murphy; Susan M Smith; Knut Schroeder; Tom Fahey
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

6.  The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults.

Authors:  Pascal Geldsetzer; Jennifer Manne-Goehler; Maja-Emilia Marcus; Cara Ebert; Zhaxybay Zhumadilov; Chea S Wesseh; Lindiwe Tsabedze; Adil Supiyev; Lela Sturua; Silver K Bahendeka; Abla M Sibai; Sarah Quesnel-Crooks; Bolormaa Norov; Kibachio J Mwangi; Omar Mwalim; Roy Wong-McClure; Mary T Mayige; Joao S Martins; Nuno Lunet; Demetre Labadarios; Khem B Karki; Gibson B Kagaruki; Jutta M A Jorgensen; Nahla C Hwalla; Dismand Houinato; Corine Houehanou; Mohamed Msaidié; David Guwatudde; Mongal S Gurung; Gladwell Gathecha; Maria Dorobantu; Albertino Damasceno; Pascal Bovet; Brice W Bicaba; Krishna K Aryal; Glennis Andall-Brereton; Kokou Agoudavi; Andrew Stokes; Justine I Davies; Till Bärnighausen; Rifat Atun; Sebastian Vollmer; Lindsay M Jaacks
Journal:  Lancet       Date:  2019-07-18       Impact factor: 79.321

7.  Efficacy and safety of triple versus dual combination blood pressure-lowering drug therapy: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Abdul Salam; Emily R Atkins; Benjumin Hsu; Ruth Webster; Anushka Patel; Anthony Rodgers
Journal:  J Hypertens       Date:  2019-08       Impact factor: 4.844

Review 8.  Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies.

Authors:  Rasha Khatib; Jon-David Schwalm; Salim Yusuf; R Brian Haynes; Martin McKee; Maheer Khan; Robby Nieuwlaat
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 9.  Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost.

Authors:  Abdul Salam; Mark D Huffman; Raju Kanukula; Esam Hari Prasad; Abhishek Sharma; David J Heller; Rajesh Vedanthan; Anubha Agarwal; Anthony Rodgers; Marc G Jaffe; Thomas R Frieden; Sandeep P Kishore
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-20       Impact factor: 3.738

10.  Risk-Factor Profile and Comorbidities in 2398 Patients With Newly Diagnosed Hypertension From the Abuja Heart Study.

Authors:  Dike B Ojji; Elena Libhaber; John J Atherton; Bolaji Abdullahi; Ada Nwankwo; Karen Sliwa
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more
  2 in total

1.  Hypertension Treatment in Nigeria (HTN) Program: rationale and design for a type 2 hybrid, effectiveness, and implementation interrupted time series trial.

Authors:  Mark D Huffman; Dike B Ojji; Abigail S Baldridge; Kasarachi Aluka-Omitiran; Ikechukwu A Orji; Gabriel L Shedul; Tunde M Ojo; Helen Eze; Grace Shedul; Eugenia N Ugwuneji; Nonye B Egenti; Rosemary C B Okoli; Boni M Ale; Ada Nwankwo; Samuel Osagie; Jiancheng Ye; Aashima Chopra; Olutobi A Sanuade; Priya Tripathi; Namratha R Kandula; Lisa R Hirschhorn
Journal:  Implement Sci Commun       Date:  2022-08-02

2.  Characteristics and Patterns of Retention in Hypertension Care in Primary Care Settings From the Hypertension Treatment in Nigeria Program.

Authors:  Jiancheng Ye; Ikechukwu A Orji; Abigail S Baldridge; Tunde M Ojo; Grace Shedul; Eugenia N Ugwuneji; Nonye B Egenti; Kasarachi Aluka-Omitiran; Rosemary C B Okoli; Helen Eze; Ada Nwankwo; Lisa R Hirschhorn; Aashima Chopra; Boni M Ale; Gabriel L Shedul; Priya Tripathi; Namratha R Kandula; Mark D Huffman; Dike B Ojji
Journal:  JAMA Netw Open       Date:  2022-09-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.